Skin & Hair

Argireline

Also known as: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

Research
Share:

Key Facts: Argireline

Category
Skin & Hair
FDA Status
Not FDA Approved
Clinical Status
Cosmetic use - Widely available
Administration
Topical (serums, creams)
Typical Dose
Limited community data available
Frequency
See research protocols
Duration
Ongoing use for maintained effects
Also Known As
Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

Mechanism of Action

Argireline is a fragment that copies the N-terminal end of SNAP-25, a protein nerve endings rely on to release acetylcholine and trigger muscle contraction. By competing for a place in the SNARE complex that powers that release, it is meant to blunt the muscle firing that folds skin into wrinkles, the same target Botox hits, but reversibly and far more weakly. The original lab work showed it really can inhibit neurotransmitter release in cell systems. The unresolved question is whether a topical cream delivers enough peptide deep enough to affect actual facial muscle, since the molecule is water-loving and does not cross the skin barrier easily.

Research Summary

The headline 30 percent wrinkle-depth reduction comes from the 2002 Blanes-Mira study, which used a 10 percent peptide oil-in-water emulsion and confirmed the SNARE-interference mechanism in cell assays. That study is the foundation of nearly every marketing claim since. But independent human work is far less flattering: a double-blind split-face trial using VISIA imaging on 19 women found that four weeks of an Argireline serum produced no statistically significant wrinkle improvement over the placebo side, and the authors concluded it is not a substitute for botulinum toxin. A 2025 review found penetration studies in direct conflict, with one reporting around 30 percent stratum-corneum passage and another only about 0.2 percent, and noted that no in vivo study actually demonstrated the muscle-inhibition mechanism it is sold on. Bottom line: real cosmetic peptide, plausible science, but the strongest positive data are old and largely tied to its developers, while better-controlled independent trials are small and underwhelming. Safety is reassuring, with no serious adverse effects reported.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

Dosing Information

Limited Research·Limited formal studies available

Typical Dosing

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research Dosing

Scientific studies

Cosmetic application guidelines

Doses from Studies

Duration

Ongoing use for maintained effects

Administration

Topical (serums, creams)

Timing & Administration

Best Time to Take

Morning and evening (topical)

Twice daily topically

Food Recommendation

With or without food

Why This Timing?

Argireline is a topical anti-wrinkle peptide. Twice daily application maintains effects.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Generally very safe
  • Mild skin irritation (rare)
  • Redness or tingling (rare)
  • Much fewer side effects than botulinum toxin

References

Research This Peptide Further

Frequently Asked Questions

What does Argireline do?

Argireline is the trade name for acetyl hexapeptide-8 (sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to Botox. It is designed to relax the muscle contractions behind expression lines. It is a cosmetic ingredient, not an FDA-approved drug, and the human efficacy data are genuinely mixed rather than settled.

How does Argireline work?

Argireline is a fragment that copies the N-terminal end of SNAP-25, a protein nerve endings rely on to release acetylcholine and trigger muscle contraction. By competing for a place in the SNARE complex that powers that release, it is meant to blunt the muscle firing that folds skin into wrinkles, the same target Botox hits, but reversibly and far more weakly. The original lab work showed it really can inhibit neurotransmitter release in cell systems. The unresolved question is whether a topical cream delivers enough peptide deep enough to affect actual facial muscle, since the molecule is water-loving and does not cross the skin barrier easily.

Is Argireline FDA approved?

No, Argireline is not currently FDA approved. Current status: Cosmetic use - Widely available

What are the side effects of Argireline?

Reported side effects include: Generally very safe, Mild skin irritation (rare), Redness or tingling (rare), Much fewer side effects than botulinum toxin. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Argireline?

Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Topical (serums, creams). Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Argireline or used in similar applications.

GHK-Cu

Clinical Trials

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.

Skin & Hair

Snap-8

Research

SNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of Argireline that adds two residues to the same SNAP-25 mimic sequence. It is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. It is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer.

Skin & Hair

Matrixyl

Research

Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.

Skin & Hair

Matrixyl 3000

Research

Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.

Skin & Hair

Copper Peptide AHK-Cu

Research

AHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.

Skin & Hair

Melanotan I

FDA

Melanotan I is the research name for afamelanotide, a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also written as [Nle4, D-Phe7]-alpha-MSH or NDP-MSH. It is the only melanocortin peptide with regulatory approval: sold as Scenesse, it was approved by the EMA in 2014 and the FDA in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). It is given as a 16 mg bioresorbable implant under the skin by a clinician, not as a tanning shortcut.

Skin & Hair

Want updates on Argireline research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.